Achieve Life Sciences (ACHV) Capital Expenditures (2010 - 2023)

Achieve Life Sciences' (ACHV) quarterly Capital Expenditures came in at $6000.0 in Q4 2023, up 100.0% on a QoQ basis from $3000.0 in Q3 2020.

Achieve Life Sciences (ACHV) Capital Expenditures (2010 - 2023) Analysis & Trends

Achieve Life Sciences (ACHV) has 12 years of Capital Expenditures data on file, last reported at $6000.0 in Q4 2023.

Quarterly Capital Expenditures changed N/A year-over-year to $6000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $21000.0 (changed N/A YoY) and the FY2025 annual result came in at $3000.0, changed N/A from the prior year.
Capital Expenditures grew to $6000.0 in Q4 2023, from $3000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $54000.0 in Q1 2019 to a low of -$2000.0 in Q2 2019.
A 3-year average of $10857.1 and a median of $3000.0 in 2020 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 700.0% in 2020, down 96.3% in 2020.
Tracing ACHV's Capital Expenditures over 3 years: stood at $1000.0 in 2019, then surged by 200.0% to $3000.0 in 2020, then surged by 100.0% to $6000.0 in 2023.
The last three Capital Expenditures figures came in at $6000.0 (Q4 2023), $3000.0 (Q3 2020), and $12000.0 (Q2 2020), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Achieve Life Sciences	330.88 Mn	330.88 Mn	-	-

Download Data